**PD inclusion criteria:** Clinically probable PD (UKPDBB), within 3.5 years of diagnosis, NINDS screening tool for atypical features
Motor/Clinical/Demographic- all

MDS-UPDRS I-IV, Hoehn and Yahr, Purdue Pegboard, 3 metre TUG, flamingo 30 sec test, Purdue Pegboard, BP/P (lying & 3 minute standing), height, weight, ethnicity, social background, past medical and family history, environmental questionnaire, drug history, smoking/alcohol history, presenting PD features, Family History, PD meds, clinical CGI, LEDD, previous medication exposure, PD diagnostic probability, Freezing of Gait Q’aire (FOG), PD screening Q’aire, Activity and Fatigue Questionnaires (subgroup).

Non-Motor/ADL- all

Schwab and England, 16-item Sniffin Odor Identification Sticks, Constipation Q’aire, Big Five Personality Inventory, Epworth Sleep Scale, RBDSQ’aire, EQ-5D, HADS, Beck Depression Inventory-II, QUIP-current-short, Big Five Inventory (BFI)

Cognitive Function- all

MMSE, Montreal Cognitive Assessment, Phonemic/Semantic category fluency, NART, IQ-CODE, FAQ (subgroup)

Wet biomarkers:
DNA, serum (all, each visit); plasma, skin biopsy, CSF (subgroup only, selected visits)

Digital (PD, RBD, control subgroup): OPDC smartphone motor test, Axivity device free-living gait, home-PSG overnight recordings, web-based cognitive testing

Imaging (PD, RBD and control subgroup): MRI and DaT SPECT baseline/longitud